Table 3.

Cox Proportional Hazard Modeling of Predictors of Clinically Significant CMV Infection Among Patients With Active SLE

	Univariate			Multivariate
	HR	95% CI	P Value	HR	95% CI	P Value
Age	1.03	0.99–1.07	.14
Female	0.90	0.12–6.96	.92
SLEDAI-2K score	0.91	0.81–1.02	.10
Neuropsychiatric SLE	2.73	0.84–8.88	.09	2.39	0.70–8.19	.17
Methylprednisolone therapy	0.97	0.13–7.47	.98
Cyclophosphamide therapy	0.58	0.16–2.09	.40
Lymphopeniaa	1.53	0.47–4.99	.48
QF-negative	0.78	0.24–2.60	.69
Lymphopeniaa at 1 mo postimmunosuppression	1.10	0.34–3.57	.88
QF-negative at 1 mo postimmunosuppression	4.89	1.06–22.74	.04	4.97	1.07–23.10	.04

Abbreviations: CMV, cytomegalovirus; HR, hazard ratio; SLE, systemic lupus erythematosus; SLEDAI, SLE Disease Activity Index 2000; QF, QuantiFERON-CMV.

^aAbsolute lymphocyte count <1000 /mm³.